1
|
Zimmermann EA, DeVet T, Cilla M, Albiol L, Kavaseri K, Andrea C, Julien C, Tiedemann K, Panahifar A, Alidokht SA, Chromik R, Komarova SV, Reinhardt DP, Zaslansky P, Willie BM. Tissue material properties, whole-bone morphology and mechanical behavior in the Fbn1 C1041G/+ mouse model of Marfan syndrome. Matrix Biol Plus 2024; 23:100155. [PMID: 39049903 PMCID: PMC11267061 DOI: 10.1016/j.mbplus.2024.100155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Revised: 06/03/2024] [Accepted: 06/04/2024] [Indexed: 07/27/2024] Open
Abstract
Marfan syndrome (MFS) is a connective tissue disorder caused by pathogenic mutations in FBN1. In bone, the protein fibrillin-1 is found in the extracellular matrix where it provides structural support of elastic fiber formation, stability for basement membrane, and regulates the bioavailability of growth factors. Individuals with MFS exhibit a range of skeletal complications including low bone mineral density and long bone overgrowth. However, it remains unknown if the bone phenotype is caused by alteration of fibrillin-1's structural function or distortion of its interactions with bone cells. To assess the structural effects of the fibrillin-1 mutation, we characterized bone curvature, microarchitecture, composition, porosity, and mechanical behavior in the Fbn1 C1041G/+ mouse model of MFS. Tibiae of 10, 26, and 52-week-old female Fbn1 C1041G/+ and littermate control (LC) mice were analyzed. Mechanical behavior was assessed via in vivo strain gauging, finite element analysis, ex vivo three-point bending, and nanoindentation. Tibial bone morphology and curvature were assessed with micro computed tomography (μCT). Bone composition was measured with Fourier transform infrared (FTIR) imaging. Vascular and osteocyte lacunar porosity were assessed by synchrotron computed tomography. Fbn1 C1041G/+ mice exhibited long bone overgrowth and osteopenia consistent with the MFS phenotype. Trabecular thickness was lower in Fbn1 C1041G/+ mice but cortical bone microarchitecture was similar in Fbn1 C1041G/+ and LC mice. Whole bone curvature was straighter below the tibio-fibular junction in the medial-lateral direction and more curved above in LC compared to Fbn1 C1041G/+ mice. The bone matrix crystallinity was 4 % lower in Fbn1 C1041G/+ mice compared to LC, implying that mineral platelets in LCs have greater crystal size and perfection than Fbn1 C1041G/+ mice. Structural and mechanical properties were similar between genotypes. Cortical diaphyseal lacunar porosity was lower in Fbn1 C1041G/+ mice compared to LC; this was a result of the average volume of an individual osteocyte lacunae being smaller. These data provide valuable insights into the bone phenotype and its contribution to fracture risk in this commonly used mouse model of MFS.
Collapse
Affiliation(s)
- Elizabeth A. Zimmermann
- Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Canada
| | - Taylor DeVet
- Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada
| | - Myriam Cilla
- Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain
- Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Zaragoza, Spain
| | - Laia Albiol
- Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Berlin, Germany
- Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Kyle Kavaseri
- Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Canada
| | - Christine Andrea
- Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada
| | - Catherine Julien
- Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Canada
| | - Kerstin Tiedemann
- Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Canada
| | - Arash Panahifar
- BioMedical Imaging and Therapy Beamline, Canadian Light Source, Saskatoon, Canada
- Department of Medical Imaging, University of Saskatchewan, Saskatoon, Canada
| | - Sima A. Alidokht
- Department of Mechanical Engineering, Memorial University of Newfoundland, St. John’s, Canada
- Department of Mining and Materials Engineering, McGill University, Montreal, Canada
| | - Richard Chromik
- Department of Mining and Materials Engineering, McGill University, Montreal, Canada
| | - Svetlana V. Komarova
- Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Canada
- Department of Biomedical Engineering, Faculty of Engineering, University of Alberta, Edmonton, Canada
| | - Dieter P. Reinhardt
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Canada
- Department of Anatomy and Cell Biology, McGill University, Montreal, Canada
| | - Paul Zaslansky
- Department for Operative, Preventive and Pediatric Dentistry, CC3 -Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Bettina M. Willie
- Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, Canada
| |
Collapse
|
2
|
Ma P, He M, Lian H, Li J, Gao Y, Wu J, Men K, Men Y, Li C. Systemic and Local Administration of a Dual-siRNA Complex Efficiently Inhibits Tumor Growth and Bone Invasion in Oral Squamous Cell Carcinoma. Mol Pharm 2024; 21:661-676. [PMID: 38175819 DOI: 10.1021/acs.molpharmaceut.3c00802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2024]
Abstract
Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral and oropharyngeal cancer cases and is characterized by high mortality and poor prognosis. RNA-based gene therapies have been developed as an emerging option for cancer treatment, but it has not been widely explored in OSCC. In this work, we developed an efficient siRNA cationic micelle DOTAP-mPEG-PCL (DMP) by self-assembling the cationic lipid DOTAP and monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (mPEG-PCL) polymer. We tested the characteristics and transformation efficiency of this micelle and combined DMP with siRNA targeting STAT3 and TGF-β to evaluate the antitumor effect and bone invasion interfering in vitro and in vivo. The average size of the DMP was 28.27 ± 1.62 nm with an average zeta potential of 54.60 ± 0.29 mV. The DMP/siRNA complex showed high delivery efficiency, with rates of 97.47 ± 0.42% for HSC-3. In vitro, the DMP/siSTAT3 complex exhibited an obvious cell growth inhibition effect detected by MTT assay (an average cell viability of 25.1%) and clonogenic assay (an average inhibition rate of 51.9%). Besides, the supernatant from HSC-3 transfected by DMP/siTGF-β complexes was found to interfere with osteoclast differentiation in vitro. Irrespective of local or systemic administration, DMP/siSTAT3+siTGF-β showed antitumor effects and bone invasion inhibition in the OSCC mice mandibular invasion model according to tumor volume assays and Micro-CT scanning. The complex constructed by DMP cationic micelles and siSTAT3+siTGF-β represents a potential RNA-based gene therapy delivery system for OSCC.
Collapse
Affiliation(s)
- Pingchuan Ma
- State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan China
| | - Mingxia He
- Joint National Laboratory for Antibody Drug Engineering, School of Medicine, Henan University, 475004 Kaifeng, China
| | - Haosen Lian
- State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan China
| | - Jingmei Li
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province China
| | - Yan Gao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province China
| | - Jieping Wu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province China
| | - Ke Men
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province China
| | - Yi Men
- State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan China
| | - Chunjie Li
- State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan China
| |
Collapse
|
3
|
Conceição F, Sousa DM, Tojal S, Lourenço C, Carvalho-Maia C, Estevão-Pereira H, Lobo J, Couto M, Rosenkilde MM, Jerónimo C, Lamghari M. The Secretome of Parental and Bone Metastatic Breast Cancer Elicits Distinct Effects in Human Osteoclast Activity after Activation of β2 Adrenergic Signaling. Biomolecules 2023; 13:biom13040622. [PMID: 37189370 DOI: 10.3390/biom13040622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 03/17/2023] [Accepted: 03/28/2023] [Indexed: 05/17/2023] Open
Abstract
The sympathetic nervous system (SNS), particularly through the β2 adrenergic receptor (β2-AR), has been linked with breast cancer (BC) and the development of metastatic BC, specifically in the bone. Nevertheless, the potential clinical benefits of exploiting β2-AR antagonists as a treatment for BC and bone loss-associated symptoms remain controversial. In this work, we show that, when compared to control individuals, the epinephrine levels in a cohort of BC patients are augmented in both earlier and late stages of the disease. Furthermore, through a combination of proteomic profiling and functional in vitro studies with human osteoclasts and osteoblasts, we demonstrate that paracrine signaling from parental BC under β2-AR activation causes a robust decrease in human osteoclast differentiation and resorption activity, which is rescued in the presence of human osteoblasts. Conversely, metastatic bone tropic BC does not display this anti-osteoclastogenic effect. In conclusion, the observed changes in the proteomic profile of BC cells under β-AR activation that take place after metastatic dissemination, together with clinical data on epinephrine levels in BC patients, provided new insights on the sympathetic control of breast cancer and its implications on osteoclastic bone resorption.
Collapse
Affiliation(s)
- Francisco Conceição
- I3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
- INEB-Instituto Nacional de Engenharia Biomédica, Universidade do Porto, 4200-135 Porto, Portugal
- ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal
| | - Daniela M Sousa
- I3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
- INEB-Instituto Nacional de Engenharia Biomédica, Universidade do Porto, 4200-135 Porto, Portugal
| | - Sofia Tojal
- I3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
- INEB-Instituto Nacional de Engenharia Biomédica, Universidade do Porto, 4200-135 Porto, Portugal
- ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal
| | - Catarina Lourenço
- I3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
- INEB-Instituto Nacional de Engenharia Biomédica, Universidade do Porto, 4200-135 Porto, Portugal
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
| | - Carina Carvalho-Maia
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal
| | - Helena Estevão-Pereira
- I3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
- INEB-Instituto Nacional de Engenharia Biomédica, Universidade do Porto, 4200-135 Porto, Portugal
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
| | - João Lobo
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal
| | - Marina Couto
- I3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
- INEB-Instituto Nacional de Engenharia Biomédica, Universidade do Porto, 4200-135 Porto, Portugal
- ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal
| | - Mette M Rosenkilde
- Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark
| | - Carmen Jerónimo
- Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre (Porto.CCC), 4200-072 Porto, Portugal
| | - Meriem Lamghari
- I3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
- INEB-Instituto Nacional de Engenharia Biomédica, Universidade do Porto, 4200-135 Porto, Portugal
- ICBAS-Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal
| |
Collapse
|
4
|
Jian L, Shi-wei L, Dan J, Juan W, Wei Z. GPR84 potently inhibits osteoclastogenesis and alleviates osteolysis in bone metastasis of colorectal cancer. J Orthop Surg Res 2023; 18:3. [PMID: 36593458 PMCID: PMC9806886 DOI: 10.1186/s13018-022-03473-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Accepted: 12/22/2022] [Indexed: 01/03/2023] Open
Abstract
The expression of GPR84 in bone marrow-derived monocytes/macrophages (BMMs) can inhibit osteoclast formation; however, its role in bone metastasis of colorectal cancer (CRC) is still unknown. To investigate the effects of GPR84 on bone metastasis of CRC, the murine CRC cell line MC-38 was injected into tibial bone marrow. We found that the expression of GPR84 in BMMs was gradually downregulated during bone metastasis of CRC, and the activation of GPR84 significantly prevented osteoclastogenesis in the tumor microenvironment. Mechanistically, the MAPK pathway mediated the effects of GPR84 on osteoclast formation. Moreover, we found that IL-11 at least partly inhibited the expression of GPR84 in the tumor microenvironment through the inactivation of STAT1. Additionally, activation of GPR84 could prevent osteolysis during bone metastasis of CRC. Our results suggest that CRC cells downregulate the expression of GPR84 in BMMs to promote osteoclastogenesis in an IL-11-dependent manner. Thus, GPR84 could be a potential therapeutic target to attenuate bone destruction induced by CRC metastasis.
Collapse
Affiliation(s)
- Li Jian
- Department of Orthopedics, General Hospital of Western Theater Command, Rongdu Avenue No. 270, Chengdu, 610000 People’s Republic of China ,grid.413856.d0000 0004 1799 3643Chengdu Medical College, Rongdu Avenue No. 601, Chengdu, 610000 People’s Republic of China
| | - Long Shi-wei
- Department of Orthopedics, General Hospital of Western Theater Command, Rongdu Avenue No. 270, Chengdu, 610000 People’s Republic of China
| | - Jing Dan
- Department of Orthopedics, General Hospital of Western Theater Command, Rongdu Avenue No. 270, Chengdu, 610000 People’s Republic of China
| | - Wu Juan
- Department of Pharmacy, General Hospital of Western Theater Command, Rongdu Avenue No. 270, Chengdu, 610000 People’s Republic of China
| | - Zheng Wei
- Department of Orthopedics, General Hospital of Western Theater Command, Rongdu Avenue No. 270, Chengdu, 610000 People’s Republic of China ,grid.413856.d0000 0004 1799 3643Chengdu Medical College, Rongdu Avenue No. 601, Chengdu, 610000 People’s Republic of China
| |
Collapse
|
5
|
Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers. Curr Oncol 2022; 29:5963-5987. [PMID: 36005209 PMCID: PMC9406569 DOI: 10.3390/curroncol29080471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2022] [Revised: 08/15/2022] [Accepted: 08/21/2022] [Indexed: 12/11/2022] Open
Abstract
Cancer, a common malignant disease, is one of the predominant causes of diseases that lead to death. Additionally, cancer is often detected in advanced stages and cannot be radically cured. Consequently, there is an urgent need for reliable and easily detectable markers to identify and monitor cancer onset and progression as early as possible. Our aim was to systematically review the relevant roles of cathepsin K (CTSK) in various possible cancers in existing studies. CTSK, a well-known key enzyme in the bone resorption process and most studied for its roles in the effective degradation of the bone extracellular matrix, is expressed in various organs. Nowadays, CTSK has been involved in various cancers such as prostate cancer, breast cancer, bone cancer, renal carcinoma, lung cancer and other cancers. In addition, CTSK can promote tumor cells proliferation, invasion and migration, and its mechanism may be related to RANK/RANKL, TGF-β, mTOR and the Wnt/β-catenin signaling pathway. Clinically, some progress has been made with the use of cathepsin K inhibitors in the treatment of certain cancers. This paper reviewed our current understanding of the possible roles of CTSK in various cancers and discussed its potential as a biomarker and/or novel molecular target for various cancers.
Collapse
|
6
|
Sadvakassova G, Tiedemann K, Steer KJD, Mikolajewicz N, Stavnichuk M, In-Kyung Lee I, Sabirova Z, Schranzhofer M, Komarova SV. Active hematopoiesis triggers exosomal release of PRDX2 that promotes osteoclast formation. Physiol Rep 2021; 9:e14745. [PMID: 33587325 PMCID: PMC7883842 DOI: 10.14814/phy2.14745] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2020] [Revised: 01/11/2021] [Accepted: 01/13/2021] [Indexed: 12/17/2022] Open
Abstract
Hematopoietic disorders, particularly hemolytic anemias, commonly lead to bone loss. We have previously reported that actively proliferating cancer cells stimulate osteoclastogenesis from late precursors in a RANKL-independent manner. We theorized that cancer cells exploit the physiological role of bone resorption to support expanding hematopoietic bone marrow and examined if hematopoietic cells can trigger osteoclastogenesis. Using phlebotomy-induced acute anemia in mice, we found strong correlation between augmented erythropoiesis and increased osteoclastogenesis. Conditioned medium (CM) from K562 erythroleukemia cells and primary mouse erythroblasts stimulated osteoclastogenesis when added to RANKL-primed precursors from mouse bone marrow or RAW264.7 cells. Using immunoblotting and mass spectrometry, PRDX2 was identified as a factor produced by erythroid cells in vitro and in vivo. PRDX2 was detected in K562-derived exosomes, and inhibiting exosomal release significantly decreased the osteoclastogenic capacity of K562 CM. Recombinant PRDX2 induced osteoclast formation from RANKL-primed primary or RAW 264.7 precursors to levels comparable to achieved with continuous RANKL treatment. Thus, increased bone marrow erythropoiesis secondary to anemia leads to upregulation of PRDX2, which is released in the exosomes and acts to induce osteoclast formation. Increased bone resorption by the osteoclasts expands bone marrow cavity, which likely plays a supporting role to increase blood cell production.
Collapse
Affiliation(s)
- Gulzhakhan Sadvakassova
- Faculty of Dentistry, McGill University, Montréal, QC, Canada.,Shriners Hospital for Children - Canada, Montréal, QC, Canada
| | - Kerstin Tiedemann
- Faculty of Dentistry, McGill University, Montréal, QC, Canada.,Shriners Hospital for Children - Canada, Montréal, QC, Canada
| | - Kieran J D Steer
- Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
| | - Nicholas Mikolajewicz
- Faculty of Dentistry, McGill University, Montréal, QC, Canada.,Shriners Hospital for Children - Canada, Montréal, QC, Canada
| | - Mariya Stavnichuk
- Shriners Hospital for Children - Canada, Montréal, QC, Canada.,Department of Biomedical Engineering, Faculty of Medicine, McGill University, Montréal, QC, Canada
| | | | - Zarina Sabirova
- Shriners Hospital for Children - Canada, Montréal, QC, Canada
| | - Matthias Schranzhofer
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada
| | - Svetlana V Komarova
- Faculty of Dentistry, McGill University, Montréal, QC, Canada.,Shriners Hospital for Children - Canada, Montréal, QC, Canada.,Department of Biomedical Engineering, Faculty of Medicine, McGill University, Montréal, QC, Canada
| |
Collapse
|
7
|
Jia W, Chen P, Cheng Y. PRDX4 and Its Roles in Various Cancers. Technol Cancer Res Treat 2019; 18:1533033819864313. [PMID: 31311441 PMCID: PMC6636222 DOI: 10.1177/1533033819864313] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Revised: 05/27/2019] [Accepted: 06/12/2019] [Indexed: 01/02/2023] Open
Abstract
Reactive oxygen species play a vital role in cell survival by regulating physiological metabolism and signal transduction of cells. The imbalance of oxidant and antioxidant states induces oxidative stress within a cell. Redox regulation and oxidative stress are closely related to survival and proliferation of stem cells, cancer cells, and cancer stem cells. Peroxiredoxin 4, a typical endoplasmic reticulum-resident 2-Cys antioxidant of peroxiredoxins, can fine-tune hydrogen peroxide catabolism which affects cell survival by affecting redox balance, oxidative protein folding, and regulation of hydrogen peroxide signaling. Recent studies revealed the overexpression of peroxiredoxin 4 in several kinds of cancers, such as breast cancer, prostate cancer, ovarian cancer, colorectal cancer, and lung cancer. And it has been demonstrated that peroxiredoxin 4 causally contributes to tumorigenesis, therapeutic resistance, metastasis, and recurrence of tumors. In this article, the characteristics of peroxiredoxin 4 in physiological functions and the cancer-related research progress of mammalian peroxiredoxin 4 is reviewed. We believe that peroxiredoxin 4 has the potential of serving as a novel target for multiple cancers.
Collapse
Affiliation(s)
- Wenqiao Jia
- Health Management Center, Shandong University Qilu Hospital, Jinan, China
| | - Pengxiang Chen
- Radiotherapy Department, Shandong University Qilu Hospital, Jinan, China
| | - Yufeng Cheng
- Radiotherapy Department, Shandong University Qilu Hospital, Jinan, China
| |
Collapse
|
8
|
Tiedemann K, Sadvakassova G, Mikolajewicz N, Juhas M, Sabirova Z, Tabariès S, Gettemans J, Siegel PM, Komarova SV. Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis. Transl Oncol 2018; 12:462-474. [PMID: 30583289 PMCID: PMC6305809 DOI: 10.1016/j.tranon.2018.11.014] [Citation(s) in RCA: 60] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 11/27/2018] [Accepted: 11/27/2018] [Indexed: 11/29/2022] Open
Abstract
Bone metastasis from breast and prostate carcinomas is facilitated by activation of bone-resorbing osteoclasts. Using proteomics approaches, we have identified peroxiredoxin-4 (PRDX4) as a cancer-secreted mediator of osteoclastogenesis. We now report characterization of L-plastin in the conditioned media (CM) of MDA-MB-231 human breast cancer cells using immunoblotting and mass spectrometry. The osteoclastogenic potential of MDA-MB-231 CM with siRNA-silenced L-plastin was significantly reduced. L-plastin was detected in cancer-derived exosomes, and inhibition of exosomal release significantly decreased the osteoclastogenic capacity of MDA-MB-231 CM. When added to osteoclast precursors primed with RANKL for 2 days, recombinant L-plastin induced calcium/NFATc1-mediated osteoclastogenesis to the levels similar to continuous treatment with RANKL. Using shRNA, we generated MDA-MB-231 cells lacking L-plastin, PRDX4, or both and injected these cell populations intratibially in CD-1 immunodeficient mice. Micro-CT and histomorphometric analysis demonstrated a complete loss of osteolysis when MDA-MB-231 cells lacking both L-plastin and PRDX4 were injected. A meta-analysis established an increase in L-plastin and PRDX4 mRNA expression in numerous human cancers, including breast and prostate carcinomas. This study demonstrates that secreted L-plastin and PRDX4 mediate osteoclast activation by human breast cancer cells.
Collapse
Affiliation(s)
- Kerstin Tiedemann
- Faculty of Dentistry, McGill University, 3640 rue University, Montreal, Quebec, Canada, H3A 0C7; Shriner's Hospital for Children - Canada, 1003 Decarie Boulevard, Montreal, Quebec H4A 0A9
| | - Gulzhakhan Sadvakassova
- Faculty of Dentistry, McGill University, 3640 rue University, Montreal, Quebec, Canada, H3A 0C7; Shriner's Hospital for Children - Canada, 1003 Decarie Boulevard, Montreal, Quebec H4A 0A9
| | - Nicholas Mikolajewicz
- Faculty of Dentistry, McGill University, 3640 rue University, Montreal, Quebec, Canada, H3A 0C7; Shriner's Hospital for Children - Canada, 1003 Decarie Boulevard, Montreal, Quebec H4A 0A9
| | - Michal Juhas
- Faculty of Dentistry, McGill University, 3640 rue University, Montreal, Quebec, Canada, H3A 0C7
| | - Zarina Sabirova
- Shriner's Hospital for Children - Canada, 1003 Decarie Boulevard, Montreal, Quebec H4A 0A9
| | - Sébastien Tabariès
- Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada, H3A 1A3; Department of Medicine, McGill University, Montreal, Quebec, Canada, H3A 1A3
| | - Jan Gettemans
- Department of Biochemistry, Faculty of Medicine and Health Sciences, Rommelaere Campus, Ghent University, Ghent, Belgium
| | - Peter M Siegel
- Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada, H3A 1A3; Department of Medicine, McGill University, Montreal, Quebec, Canada, H3A 1A3; Department of Biochemistry, McGill University, Montreal, Quebec, Canada, H3A 1A3
| | - Svetlana V Komarova
- Faculty of Dentistry, McGill University, 3640 rue University, Montreal, Quebec, Canada, H3A 0C7; Shriner's Hospital for Children - Canada, 1003 Decarie Boulevard, Montreal, Quebec H4A 0A9.
| |
Collapse
|
9
|
Boraschi-Diaz I, Mort JS, Brömme D, Senis YA, Mazharian A, Komarova SV. Collagen type I degradation fragments act through the collagen receptor LAIR-1 to provide a negative feedback for osteoclast formation. Bone 2018; 117:23-30. [PMID: 30217615 DOI: 10.1016/j.bone.2018.09.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 08/09/2018] [Accepted: 09/10/2018] [Indexed: 12/31/2022]
Abstract
The major organic component of bone is collagen type I. Osteoclasts are terminally differentiated multinucleated cells of hematopoietic origin that are essential for physiological development of bone and teeth. We examined if osteoclast differentiation from murine bone marrow precursors is affected by collagen type I, or by its degradation products produced by human recombinant cathepsin K. Osteoclasts formation was dose-dependently inhibited in the presence of full length collagen type I or its 30-75 kDa degradation products added to the osteoclast differentiation media for the duration of an experiment. Collagen degradation fragments signaled through SH-2 phosphatases, inhibiting calcium signaling and NFATc1 translocation in osteoclast precursors. Osteoclasts and their precursors expressed a collagen receptor of leukocyte receptor complex family, LAIR-1. Importantly, collagen fragments failed to inhibit osteoclast formation from LAIR-1 deficient murine osteoclast precursors. This study demonstrates that collagen degradation fragments inhibit osteoclast formation acting through LAIR-1, providing a novel mechanism for the physiologically-relevant negative control of osteoclastogenesis.
Collapse
Affiliation(s)
- Iris Boraschi-Diaz
- Faculty of Dentistry, McGill University, Montreal, Quebec, Canada; Shriners Hospital for Children-Canada, Montreal, Quebec H3G 1A6, Canada
| | - John S Mort
- Shriners Hospital for Children-Canada, Montreal, Quebec H3G 1A6, Canada
| | - Dieter Brömme
- Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Yotis A Senis
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| | - Alexandra Mazharian
- Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| | - Svetlana V Komarova
- Faculty of Dentistry, McGill University, Montreal, Quebec, Canada; Shriners Hospital for Children-Canada, Montreal, Quebec H3G 1A6, Canada.
| |
Collapse
|
10
|
Inhibitory effects of low intensity pulsed ultrasound on osteoclastogenesis induced in vitro by breast cancer cells. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2018; 37:197. [PMID: 30126457 PMCID: PMC6102871 DOI: 10.1186/s13046-018-0868-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Accepted: 08/07/2018] [Indexed: 12/17/2022]
Abstract
Background Bone tissue is one of the main sites for breast metastasis; patients diagnosed with advanced breast cancer mostly develop bone metastasis characterized by severe osteolytic lesions, which heavily influence their life quality. Low Intensity Pulsed Ultrasound (LIPUS) is a form of mechanical energy able to modulate various molecular pathways both in cancer and in health cells. The purpose of the present study was to evaluate for the first time, the ability of LIPUS to modulate osteolytic capability of breast cancer cells. Methods Two different approaches were employed: a) Indirect method -conditioned medium obtained by MDA-MB-231 cell line treated or untreated with LIPUS was used to induce osteoclast differentiation of murine macrophage Raw264.7 cell line; and b) Direct method -MDA-MB-231 were co-cultured with Raw264.7 cells and treated or untreated with LIPUS. Results LIPUS treatment impaired MDA-MB-231 cell dependentosteoclast differentiation and produced a reduction of osteoclast markers such as Cathepsin K, Matrix Metalloproteinase 9 and Tartrate Resistant Acid Phosphatase, suggesting its role as an effective and safe adjuvant in bone metastasis management. Conclusion LIPUS treatment could be a good and safety therapeutic adjuvant in osteolyitic bone metastasis not only for the induction properties of bone regeneration, but also for the reduction of osteolysis.
Collapse
|
11
|
Ma YV, Lam C, Dalmia S, Gao P, Young J, Middleton K, Liu C, Xu H, You L. Mechanical regulation of breast cancer migration and apoptosis via direct and indirect osteocyte signaling. J Cell Biochem 2018; 119:5665-5675. [DOI: 10.1002/jcb.26745] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Accepted: 01/29/2018] [Indexed: 01/01/2023]
Affiliation(s)
- Yu‐Heng V. Ma
- Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoOntarioCanada
| | - Candy Lam
- Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoOntarioCanada
| | - Shreyash Dalmia
- Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoOntarioCanada
| | - Peter Gao
- Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoOntarioCanada
| | - Jacob Young
- Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoOntarioCanada
| | - Kevin Middleton
- Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoOntarioCanada
| | - Chao Liu
- Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoOntarioCanada
| | - Henry Xu
- Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoOntarioCanada
| | - Lidan You
- Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoOntarioCanada
- Department of Mechanical and Industrial EngineeringUniversity of TorontoTorontoOntarioCanada
| |
Collapse
|
12
|
Strazic-Geljic I, Guberovic I, Didak B, Schmid-Antomarchi H, Schmid-Alliana A, Boukhechba F, Bouler JM, Scimeca JC, Verron E. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases. Biochem Pharmacol 2016; 116:11-21. [DOI: 10.1016/j.bcp.2016.06.020] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Accepted: 06/30/2016] [Indexed: 11/29/2022]
|
13
|
Jiang Z, Wu S, Wu X, Zhong J, Lv A, Jiao J, Chen Z. Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine toleranceviaµ-opioid receptor. Int J Cancer 2015; 138:2013-20. [PMID: 26566757 DOI: 10.1002/ijc.29927] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2015] [Revised: 10/12/2015] [Accepted: 10/20/2015] [Indexed: 02/01/2023]
Affiliation(s)
- Zongming Jiang
- Department of Anesthesiology; Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University); Shaoxing Zhejiang 312000 China
| | - Shaoyong Wu
- Department of Anesthesiology; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong 510000 China
| | - Xiujuan Wu
- Department of Nephrology; Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University); Shaoxing Zhejiang 312000 China
| | - Junfeng Zhong
- Department of Anesthesiology; Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University); Shaoxing Zhejiang 312000 China
| | - Anqing Lv
- Department of Anesthesiology; Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University); Shaoxing Zhejiang 312000 China
| | - Jing Jiao
- Department of Anesthesiology; Shanghai Obstetrics and Gynecology Hospital, Fudan University; Shanghai 200011 China
| | - Zhonghua Chen
- Department of Anesthesiology; Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University); Shaoxing Zhejiang 312000 China
| |
Collapse
|
14
|
Sutherland A, Forsyth A, Cong Y, Grant L, Juan TH, Lee JK, Klimowicz A, Petrillo SK, Hu J, Chan A, Boutillon F, Goffin V, Egan C, Tang PA, Cai L, Morris D, Magliocco A, Shemanko CS. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation. J Natl Cancer Inst 2015; 108:djv338. [PMID: 26586670 DOI: 10.1093/jnci/djv338] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 10/15/2015] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Metastasis to the bone is a deleterious aspect of breast cancer and is a preferred site that results in bone loss. Hormones such as prolactin (PRL) have not yet been studied for their role in modulating the secondary tumor bone microenvironment. METHODS We used quantitative immunohistochemistry with 134 samples of human primary breast cancer and 17 matched primary breast cancers and bone metastases. A Cox proportional hazards regression model was fitted to evaluate the associations between high prolactin receptor (PRLR) expression and time to bone metastasis, adjusting for estrogen receptor status, lymph node status, and chemotherapy status. We assessed osteoclast differentiation, osteoclast size, and measured pit formation in dentine slices. Statistical tests were two-sided. RESULTS High PRLR expression in the primary breast tumor was associated with a shorter time to metastasis that includes bone (PRLRAQUA Max-per 100 unit hazard ratio = 1.04, 95% confidence interval = 1.00 to 1.07, P = .03). We observed the PRLR in rare samples of bone metastases and matched primary breast cancer. PRL treatment of breast cancer cells induced osteoclast differentiation and bone lysis via secreted factors and was abrogated by a PRLR antagonist (delta1-9-G129R-hPRL). We demonstrated that sonic hedgehog is a PRL-regulated cytokine in breast cancer cells and part of the mechanism that induces osteoclast differentiation. CONCLUSIONS Our evidence indicates that PRL-PRLR can escalate the impact of breast cancer on bone metastasis and that the presence of the PRLR in the tumor microenvironment of breast cancer bone metastasis has the potential to modulate the microenvironment to induce lytic osteoclast formation.
Collapse
Affiliation(s)
- Ashley Sutherland
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Amanda Forsyth
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Yingying Cong
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Laurel Grant
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Tzu-Hua Juan
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Jae K Lee
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Alexander Klimowicz
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Stephanie K Petrillo
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Jinghui Hu
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Angela Chan
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Florence Boutillon
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Vincent Goffin
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Cay Egan
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Patricia A Tang
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Li Cai
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Don Morris
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Anthony Magliocco
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| | - Carrie S Shemanko
- Affiliations of authors: University of Calgary, Department of Biological Sciences and Arnie Charbonneau Cancer Institute , Calgary , Canada (AS, AF, YC, LG, CSS); H. Lee Moffitt Cancer Center & Research Institute, Department of Biostatistics and Bioinformatics , Tampa, FL (THJ, JKL); Tom Baker Cancer Centre, Translational Labs , Calgary , Canada (AK, SKP, JH, AC, CE, PAT, DM, AM); Université Paris Descartes, Inserm U1151, Institut Necker Enfants Malades (INEM), Team "Pathophysiology of PRL/GH" , Paris , France (FB, VG); Medical Department of Breast Oncology, The Tumor Hospital of Harbin Medical University , Harbin , China (YC, LC); H. Lee Moffitt Cancer Center & Research Institute, Department of Anatomical Pathology , Tampa, FL (AM)
| |
Collapse
|
15
|
Rafiei S, Tiedemann K, Tabariès S, Siegel PM, Komarova SV. Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis. Cancer Lett 2015; 361:262-70. [PMID: 25779674 DOI: 10.1016/j.canlet.2015.03.012] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Revised: 03/06/2015] [Accepted: 03/10/2015] [Indexed: 12/01/2022]
Abstract
Bone is a common site of metastasis from breast and prostate carcinoma, where activation of bone resorbing osteoclasts is important for cancer progression. A large body of evidence indicates that soluble factors produced by the cancer cells act to promote osteoclast formation. Using mass spectrometry, we identified peroxiredoxin (PRDX) as a secreted mediator of cancer-induced osteoclastogenesis. Both breast (MCF7 and MDA-MB-231) and prostate (PC3 and LNCaP) carcinoma cells secreted PRDX4. PRDX4 knockdown using shRNA (shPRDX4) diminished PRDX4 secretion from MDA-MB-231 and PC3 cells and significantly decreased the ability of cancer-derived factors to induce osteoclast formation from late precursors in vitro. Tibial injection of shPRDX4 PC3 cells led to the development of significantly smaller osteolytic lesions characterized by significantly reduced osteoclast numbers compared to control PC3 cells. A meta-analysis demonstrated an increase in PRDX4 mRNA expression in carcinoma and metastatic breast and prostate tissues. Moreover, high expression of PRDX4 in the primary breast tumor was consistently associated with metastasis at 5 years. These data identify a novel function of secreted PRDX4 in mediating osteoclast activation by cancer cells.
Collapse
Affiliation(s)
- Shahrzad Rafiei
- Department of Anatomy and Cell Biology, McGill University, Montréal, Quebec, Canada; Shriners Hospital for Children-Canada, Montréal, Quebec H3G IA6, Canada
| | - Kerstin Tiedemann
- Shriners Hospital for Children-Canada, Montréal, Quebec H3G IA6, Canada; Faculty of Dentistry, McGill University, Montréal, Quebec, Canada
| | - Sébastien Tabariès
- Goodman Cancer Research Centre, McGill University, Montréal, Quebec, Canada
| | - Peter M Siegel
- Goodman Cancer Research Centre, McGill University, Montréal, Quebec, Canada; Department of Biochemistry, McGill University, Montréal, Quebec, Canada; Department of Medicine, McGill University, Montréal, Quebec, Canada
| | - Svetlana V Komarova
- Department of Anatomy and Cell Biology, McGill University, Montréal, Quebec, Canada; Shriners Hospital for Children-Canada, Montréal, Quebec H3G IA6, Canada; Faculty of Dentistry, McGill University, Montréal, Quebec, Canada.
| |
Collapse
|
16
|
Transforming growth factor-β synthesized by stromal cells and cancer cells participates in bone resorption induced by oral squamous cell carcinoma. Biochem Biophys Res Commun 2015; 458:777-82. [DOI: 10.1016/j.bbrc.2015.02.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 02/03/2015] [Indexed: 12/21/2022]
|
17
|
Shafieyan Y, Tiedemann K, Komarova SV, Quinn TM. Effects of low frequency cyclic mechanical stretching on osteoclastogenesis. J Biomech 2014; 47:3750-7. [DOI: 10.1016/j.jbiomech.2014.06.028] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2013] [Revised: 06/16/2014] [Accepted: 06/20/2014] [Indexed: 12/26/2022]
|
18
|
Tiedemann K, Boraschi-Diaz I, Rajakumar I, Kaur J, Roughley P, Reinhardt DP, Komarova SV. Fibrillin-1 directly regulates osteoclast formation and function by a dual mechanism. J Cell Sci 2014; 126:4187-94. [PMID: 24039232 DOI: 10.1242/jcs.127571] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Mutations in the fibrillin-1 gene give rise to a number of heritable disorders, which are all characterized by various malformations of bone as well as manifestations in other tissues. However, the role of fibrillin-1 in the development and homeostasis of bone is not well understood. Here, we examined the role of fibrillin-1 in regulating osteoclast differentiation from primary bone-marrow-derived precursors and monocytic RAW 264.7 cells. The soluble N-terminal half of fibrillin-1 (rFBN1-N) strongly inhibited osteoclastogenesis, whereas the C-terminal half (rFBN1-C) did not. By contrast, when rFBN1-N was immobilized on calcium phosphate, it did not affect osteoclastogenesis but modulated osteoclast resorptive activity, which was evident by a larger number of smaller resorption pits. Using a panel of recombinant sub-fragments spanning rFBN1-N, we localized an osteoclast inhibitory activity to the 63 kDa subfragment rF23 comprising the N-terminal region of fibrillin-1. Osteoclastic resorption led to the generation of small fibrillin-1 fragments that were similar to those identified in human vertebral bone extracts. rF23, but not rFBN1-N, was found to inhibit the expression of cathepsin K, matrix metalloproteinase 9 and Dcstamp in differentiating osteoclasts. rFBN1-N, but not rF23, exhibited interaction with RANKL. Excess RANKL rescued the inhibition of osteoclastogenesis by rFBN1-N. By contrast, rF23 disrupted RANKL-induced Ca(2+) signaling and activation of transcription factor NFATc1. These studies highlight a direct dual inhibitory role of N-terminal fibrillin-1 fragments in osteoclastogenesis, the sequestration of RANKL and the inhibition of NFATc1 signaling, demonstrating that osteoclastic degradation of fibrillin-1 provides a potent negative feedback that limits osteoclast formation and function.
Collapse
Affiliation(s)
- Kerstin Tiedemann
- Faculty of Dentistry, McGill University, 3640 rue University, Montreal, Quebec, Canada, H3A 0C7
| | | | | | | | | | | | | |
Collapse
|
19
|
Rafiei S, Komarova SV. Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells. BMC Cancer 2013; 13:605. [PMID: 24370273 PMCID: PMC3881018 DOI: 10.1186/1471-2407-13-605] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Accepted: 12/16/2013] [Indexed: 11/10/2022] Open
Abstract
Background Advanced prostate cancer commonly metastasizes to bone leading to osteoblastic and osteolytic lesions. Although an osteolytic component governed by activation of bone resorbing osteoclasts is prominent in prostate cancer metastasis, the molecular mechanisms of prostate cancer-induced osteoclastogenesis are not well-understood. Methods We studied the effect of soluble mediators released from human prostate carcinoma cells on osteoclast formation from mouse bone marrow and RAW 264.7 monocytes. Results Soluble factors released from human prostate carcinoma cells significantly increased viability of naïve bone marrow monocytes, as well as osteoclastogenesis from precursors primed with receptor activator of nuclear factor κ-B ligand (RANKL). The prostate cancer-induced osteoclastogenesis was not mediated by RANKL as it was not inhibited by osteoprotegerin (OPG). However inhibition of TGFβ receptor I (TβRI), or macrophage-colony stimulating factor (MCSF) resulted in attenuation of prostate cancer-induced osteoclastogenesis. We characterized the signaling pathways induced in osteoclast precursors by soluble mediators released from human prostate carcinoma cells. Prostate cancer factors increased basal calcium levels and calcium fluctuations, induced nuclear localization of nuclear factor of activated t-cells (NFAT)c1, and activated prolonged phosphorylation of ERK1/2 in RANKL-primed osteoclast precursors. Inhibition of calcium signaling, NFATc1 activation, and ERK1/2 phosphorylation significantly reduced the ability of prostate cancer mediators to stimulate osteoclastogenesis. Conclusions This study reveals the molecular mechanisms underlying the direct osteoclastogenic effect of prostate cancer derived factors, which may be beneficial in developing novel osteoclast-targeting therapeutic approaches.
Collapse
Affiliation(s)
| | - Svetlana V Komarova
- Department of Anatomy and Cell Biology, Faculty of Medicine, 3640 University Street, Montreal, Quebec H3A 2B2, Canada.
| |
Collapse
|
20
|
Dedes PG, Kanakis I, Gialeli C, Theocharis AD, Tsegenidis T, Kletsas D, Tzanakakis GN, Karamanos NK. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease. Biochim Biophys Acta Gen Subj 2013; 1830:3625-34. [PMID: 23395844 DOI: 10.1016/j.bbagen.2013.01.020] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2012] [Revised: 01/23/2013] [Accepted: 01/28/2013] [Indexed: 01/06/2023]
Abstract
BACKGROUND The interactions between metastatic breast cancer cells and host cells of osteoclastic lineage in bone microenvironment are essential for osteolysis. In vitro studies to evaluate pharmacological agents are mainly limited to their direct effects on cell lines. To mimic the communication between breast cancer cells and human osteoclasts, a simple and reproducible cellular model was established to evaluate the effects of zoledronate (zoledronic acid, ZOL), a bisphosphonate which exerts antiresorptive properties. METHODS Human precursor osteoclasts were cultured on bone-like surfaces in the presence of stimuli (sRANKL, M-CSF) to ensure their activation. Furthermore, immature as well as activated osteoclasts were co-cultured with MDA-MB-231 breast cancer cells. TRAP5b and type I collagen N-terminal telopeptide (NTx) were used as markers. Osteoclasts' adhesion to bone surface and subsequent bone breakdown were evaluated by studying the expression of cell surface receptors and certain functional matrix macromolecules in the presence of ZOL. RESULTS ZOL significantly suppresses the precursor osteoclast maturation, even when the activation stimuli (sRANKL and M-SCF) are present. Moreover, it significantly decreases bone osteolysis and activity of MMPs as well as precursor osteoclast maturation by breast cancer cells. Additionally, ZOL inhibits the osteolytic activity of mature osteoclasts and the expression of integrin β3, matrix metalloproteinases and cathepsin K, all implicated in adhesion and bone resorption. CONCLUSIONS ZOL exhibits a beneficial inhibitory effect by restricting activation of osteoclasts, bone particle decomposition and the MMP-related breast cancer osteolysis. GENERAL SIGNIFICANCE The proposed cellular model can be reliably used for enhancing preclinical evaluation of pharmacological agents in metastatic bone disease.
Collapse
Affiliation(s)
- P G Dedes
- Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Hernandez LL, Gregerson KA, Horseman ND. Mammary gland serotonin regulates parathyroid hormone-related protein and other bone-related signals. Am J Physiol Endocrinol Metab 2012; 302:E1009-15. [PMID: 22318950 PMCID: PMC3774078 DOI: 10.1152/ajpendo.00666.2011] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Breast cells drive bone demineralization during lactation and metastatic cancers. A shared mechanism among these physiological and pathological states is endocrine secretion of parathyroid hormone-related protein (PTHrP), which acts through osteoblasts to stimulate osteoclastic bone demineralization. The regulation of PTHrP has not been accounted for fully by any conventional mammotropic stimuli or tumor growth factors. Serotonin (5-HT) synthesis within breast epithelial cells is induced during lactation and in advancing breast cancer. Here we report that serotonin deficiency (knockout of tryptophan hydroxylase-1) results in a reduction of mammary PTHrP expression during lactation, which is rescued by restoring 5-HT synthesis. 5-HT induced PTHrP expression in lactogen-primed mammary epithelial cells from either mouse or cow. In human breast cancer cells 5-HT induced both PTHrP and the metastasis-associated transcription factor Runx2/Cbfa1. Based on receptor expression and pharmacological evidence, the 5-HT2 receptor type was implicated as being critical for induction of PTHrP and Runx2. These results connect 5-HT synthesis to the induction of bone-regulating factors in the normal mammary gland and in breast cancer cells.
Collapse
Affiliation(s)
- Laura L Hernandez
- Department of Molecular and Cellular Physiology, University of Cincinnati, Cincinnati, Ohio, USA
| | | | | |
Collapse
|
22
|
Bundred N. Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev 2012; 38:776-86. [PMID: 22370427 DOI: 10.1016/j.ctrv.2012.02.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2011] [Revised: 01/13/2012] [Accepted: 02/02/2012] [Indexed: 11/16/2022]
Abstract
Bone health is an emerging concern in the early breast cancer setting. Current adjuvant therapies, especially hormonal therapies in premenopausal patients (e.g. goserelin) and aromatase inhibitors in postmenopausal patients, have been associated with substantial decreases in bone mineral density that may place patients at risk for fractures. Bisphosphonates--and the recently approved anti-RANKL antibody, denosumab--have both demonstrated activity for the treatment of postmenopausal osteoporosis and cancer treatment-induced bone loss (CTIBL) in breast cancer patients, although neither has received widespread approval specifically for CTIBL. However, some bisphosphonates, especially the nitrogen-containing bisphosphonate zoledronic acid, have also demonstrated clinically meaningful anticancer effects in patients receiving adjuvant hormonal therapy for breast cancer and in other oncology settings. The effects of denosumab on cancer disease outcomes in the adjuvant setting remain to be established. This discrepancy has created a dilemma in terms of how to evaluate the complete benefit:risk profile of bone-health management options in the adjuvant breast cancer setting. This review summarises the current data on the course of cancer in clinical trials of the antiresorptive agents and provides important insight into the relative anticancer potential of the various therapies.
Collapse
Affiliation(s)
- Nigel Bundred
- Department of Surgery, University Hospital of South Manchester, Manchester, UK.
| |
Collapse
|
23
|
Hussein O, Tiedemann K, Murshed M, Komarova SV. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett 2012; 314:176-84. [DOI: 10.1016/j.canlet.2011.09.026] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2010] [Revised: 09/20/2011] [Accepted: 09/21/2011] [Indexed: 11/15/2022]
|
24
|
Ouellet V, Tiedemann K, Mourskaia A, Fong JE, Tran-Thanh D, Amir E, Clemons M, Perbal B, Komarova SV, Siegel PM. CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. THE AMERICAN JOURNAL OF PATHOLOGY 2011; 178:2377-88. [PMID: 21514448 DOI: 10.1016/j.ajpath.2011.01.033] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2010] [Revised: 01/05/2011] [Accepted: 01/13/2011] [Indexed: 10/18/2022]
Abstract
Bone is a preferred site for breast cancer metastasis, causing pain, fractures, spinal cord compressions, and hypercalcemia, all of which can significantly diminish the patient's quality of life. We identified CCN3 as a novel factor that is highly expressed in bone metastatic breast cancer cells from a xenograft mouse model and in bone metastatic lesions from patients with breast cancer. We demonstrate that CCN3 overexpression enhances the ability of weakly bone metastatic breast cancer cells to colonize and grow in the bone without altering their growth in the mammary fat pad. We further demonstrated that human recombinant CCN3 inhibits osteoblast differentiation from primary bone marrow cultures, leading to a higher receptor activator of NF-κB ligand (RANKL)/osteoprotegerin (OPG) ratio. In conjunction with its ability to impair osteoblast differentiation, we uncovered a novel role for CCN3 in promoting osteoclast differentiation from RANKL-primed monocyte precursors. CCN3 exerts its pro-osteoclastogenic effects by promoting calcium oscillations and nuclear factor of activated T cells c1 (NFATc1) nuclear translocation. Together, these results demonstrate that CCN3 regulates the differentiation of bone resident cells to create a resorptive environment that promotes the formation of osteolytic breast cancer metastases.
Collapse
Affiliation(s)
- Véronique Ouellet
- Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Hussein O, Komarova SV. Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal 2011; 5:85-99. [PMID: 21484191 DOI: 10.1007/s12079-011-0117-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2010] [Accepted: 01/05/2011] [Indexed: 10/25/2022] Open
Abstract
Breast carcinoma is the most common cancer of women. Bones are often involved with breast carcinoma metastases with the resulting morbidity and reduced quality of life. Breast cancer cells arriving at bone tissues mount supportive microenvironment by recruiting and modulating the activity of several host tissue cell types including the specialized bone cells osteoblasts and osteoclasts. Pathologically activated osteoclasts produce osteolytic lesions associated with bone pain, pathological fractures, cord compression and other complications of metastatic breast carcinoma at bone. Over the last decade there has been enormous growth of knowledge in the field of osteoclasts biology both in the physiological state and in the tumor microenvironment. This knowledge allowed the development and implementation of several targeted therapeutics that expanded the armamentarium of the oncologists dealing with the metastases-associated osteolytic disease. While the interactions of cancer cells with resident bone cells at the established metastatic gross lesions are well-studied, the preclinical events that underlie the progression of disseminated tumor cells into micrometastases and then into clinically-overt macrometastases are just starting to be uncovered. In this review, we discuss the established information and the most recent discoveries in the pathogenesis of osteolytic metastases of breast cancer, as well as the corresponding investigational drugs that have been introduced into clinical development.
Collapse
Affiliation(s)
- Osama Hussein
- Faculty of Dentistry, McGill University, Montreal, Quebec, H3A 1A4, Canada
| | | |
Collapse
|
26
|
Fong JE, Le Nihouannen D, Komarova SV. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase. J Biol Chem 2010; 285:31427-34. [PMID: 20679341 PMCID: PMC2951217 DOI: 10.1074/jbc.m110.114496] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
During breast cancer metastasis to bone, tumor cells home to bone marrow, likely targeting the stem cell niche, and stimulate osteoclasts, which mediate osteolysis required for tumor expansion. Although osteoblasts contribute to the regulation of the hematopoietic stem cell niche and control osteoclastogenesis through production of proresorptive cytokine RANKL (receptor activator of NF-κB ligand), their role in cancer metastases to bone is not fully understood. C57BL/6J mouse bone marrow cells were treated for 3–12 days with ascorbic acid (50 μg/ml) in the presence or absence of 10% medium conditioned by breast carcinoma cells MDA-MB-231, 4T1, or MCF7. Treatment with cancer-derived factors resulted in a sustained 40–60% decrease in osteoblast differentiation markers, compared with treatment with ascorbic acid alone, and induced an osteoclastogenic change in the RANKL/osteoprotegerin ratio. Importantly, exposure of bone cells to breast cancer-derived factors stimulated the subsequent attachment of cancer cells to immature osteoblasts. Inhibition of γ-secretase using pharmacological inhibitors DAPT and Compound E completely reversed cancer-induced osteoclastogenesis as well as cancer-induced enhancement of cancer cell attachment, identifying γ-secretase activity as a key mediator of these effects. Thus, we have uncovered osteoblasts as critical intermediary of premetastatic signaling by breast cancer cells and pinpointed γ-secretase as a robust target for developing therapeutics potentially capable of reducing both homing and progression of cancer metastases to bone.
Collapse
Affiliation(s)
- Jenna E Fong
- Faculty of Dentistry, McGill University, Montreal, Quebec H3A 1A4, Canada
| | | | | |
Collapse
|
27
|
Rose AAN, Siegel PM. Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 2010; 6:55-74. [DOI: 10.2217/fon.09.138] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
In the past decade, our understanding of the molecular mechanisms that underlie breast cancer pathology and progression has dramatically improved. Using this knowledge, we have identified additional targets and developed novel therapeutic interventions in breast cancer. Together, these translational research efforts are helping to usher us into an age of personalized cancer therapy. Metastasis to bone is a common and devastating consequence of breast cancer. Bisphosphonates, which represent the current gold standard in bone metastasis therapies, are being improved with newer and more efficacious generations of these compounds being developed. Breast cancer growth in the bone requires activation of various signaling pathways in both cancer cells and stromal cells, including those that are stimulated by TGF-β and RANKL, and mediated through the Src tyrosine kinase. Bone cells and cancer cells alike express promising targets for therapeutic intervention, including Cathepsin K, CXCR4 and GPNMB. In this article we discuss the molecular mechanisms behind these pro-metastatic molecules and review the most recent findings in the clinical development of their associated targeted therapies.
Collapse
Affiliation(s)
- April AN Rose
- Departments of Medicine, Goodman Cancer Centre, McGill University, QC H3A 1A3, Canada
| | - Peter M Siegel
- Departments of Medicine and Biochemistry, Goodman Cancer Centre, McGill University, 1160 Pine Ave. West, Room 513, Montréal, QC H3A 1A3, Canada
| |
Collapse
|
28
|
Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol 2009; 310:71-81. [PMID: 19616059 DOI: 10.1016/j.mce.2009.07.004] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2009] [Revised: 07/03/2009] [Accepted: 07/08/2009] [Indexed: 01/12/2023]
Abstract
Bone metastatic disease is a late-stage event of many common cancers, such as those of prostate and breast. It is incurable and causes severe morbidity. Tumor and bone interact in a vicious cycle, where tumor-secreted factors stimulate bone cells, which in turn release growth factors and cytokines that act back on the tumor cells. Within the vicious cycle are many potential therapeutic targets for novel treatment of bone metastatic disease. Therapeutic strategies can be oriented to inhibit bone cells (osteoclasts and osteoblasts) or tumor responses to factors enriched in the bone microenvironment. Many publications, especially from pre-clinical animal models, show that this approach, especially combination treatments, can reduce tumor burden and tumor-derived bone lesions. This supports a novel paradigm: tumor growth can be effectively inhibited by targeting the bone and its microenvironment rather than the tumor itself alone.
Collapse
Affiliation(s)
- Sandra Casimiro
- Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisboa, Portugal
| | | | | |
Collapse
|
29
|
Tiedemann K, Hussein O, Sadvakassova G, Guo Y, Siegel PM, Komarova SV. Breast cancer-derived factors stimulate osteoclastogenesis through the Ca2+/protein kinase C and transforming growth factor-beta/MAPK signaling pathways. J Biol Chem 2009; 284:33662-70. [PMID: 19801662 DOI: 10.1074/jbc.m109.010785] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Breast cancer commonly metastasizes to bone where its growth depends on the action of bone-resorbing osteoclasts. We have previously shown that breast cancer cells secrete factors able to directly stimulate osteoclastogenesis from receptor activator of nuclear factor kappaB ligand (RANKL)-primed precursors and that transforming growth factor-beta (TGFbeta) plays a permissive role in this process. Now, we evaluate the signaling events triggered in osteoclast precursors by soluble factors produced by MDA-MB-231 human breast carcinoma cells. In mouse bone marrow cultures and RAW 264.7 murine monocytic cells, MDA-MB-231-derived factors increased osteoclast number, size, and nucleation. These factors failed to induce Smad2 phosphorylation, and short interfering RNAs against Smad4 did not affect their ability to induce osteoclastogenesis. In contrast, MDA-MB-231 factors induced phosphorylation of p38 and ERK1/2, and pharmacological inhibitors against p38 (SB203580) and MEK1/2 (PD98059) impeded the osteoclastogenic effects of cancer-derived factors. Neutralizing antibodies against TGFbeta attenuated p38 activation, whereas activation of ERK1/2 was shortened in duration, but not decreased in amplitude. ERK1/2 phosphorylation induced by cancer-derived factors was blocked by MEK1/2 inhibitor, but not by Ras (manumycin A) or Raf (GW5074) inhibitors. Inhibition of protein kinase Calpha using Gö6976 prevented both ERK1/2 phosphorylation and osteoclast formation in response to MDA-MB-231-derived factors. Using microspectrofluorimetry of fura-2-AM-loaded osteoclast precursors, we have found that cancer-derived factors, similar to RANKL, induced sustained oscillations in cytosolic free calcium. The calcium chelator BAPTA prevented calcium elevations and osteoclast formation in response to MDA-MB-231-derived factors. Thus, we have shown that breast cancer-derived factors induce osteoclastogenesis through the activation of calcium/protein kinase Calpha and TGFbeta-dependent ERK1/2 and p38 signaling pathways.
Collapse
Affiliation(s)
- Kerstin Tiedemann
- Faculty of Dentistry, McGill University, Montreal, Quebec H3A 2B2, Canada
| | | | | | | | | | | |
Collapse
|
30
|
Georges S, Ruiz Velasco C, Trichet V, Fortun Y, Heymann D, Padrines M. Proteases and bone remodelling. Cytokine Growth Factor Rev 2008; 20:29-41. [PMID: 19041277 DOI: 10.1016/j.cytogfr.2008.11.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Bone remodelling is regulated by osteogenic cells which act individually through cellular and molecular interaction. These interactions can be established either through a cell-cell contact, involving molecules of the integrin family, or by the release of many polypeptidic factors and/or their soluble receptor chains. Proteolytic shedding of membrane-associated proteins regulates the physiological activity of numerous proteins. Proteases located on the plasma membrane, either as transmembrane proteins or anchored to cell-surface molecules, serve as activators or inhibitors of different cellular and physiological processes. This review will focus on the role of the proteases implicated in bone remodelling either through the proteolytic degradation of the extracellular matrix or through their relations with osteogenic factors. Their implication in bone tumor progression will be also considered.
Collapse
Affiliation(s)
- S Georges
- Université de Nantes, Nantes Atlantique Universités, France
| | | | | | | | | | | |
Collapse
|